Arcturus Net Income From Continuing Ops from 2010 to 2024
| ARCT Stock | USD 16.91 0.16 0.94% |
Net Income From Continuing Ops | First Reported 2016-12-31 | Previous Quarter -26.8 M | Current Value -17.2 M | Quarterly Volatility 32.8 M |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Net Income From Continuing Ops |
Latest Arcturus Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Arcturus Therapeutics Holdings over the last few years. It is Arcturus Therapeutics' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Arcturus Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (14,870,503) | |
| Geometric Mean | 22,294,466 | |
| Coefficient Of Variation | (467.30) | |
| Mean Deviation | 38,908,264 | |
| Median | (10,548,000) | |
| Standard Deviation | 69,489,803 | |
| Sample Variance | 4828.8T | |
| Range | 308M | |
| R-Value | 0.14 | |
| Mean Square Error | 5092.3T | |
| R-Squared | 0.02 | |
| Significance | 0.61 | |
| Slope | 2,238,733 | |
| Total Sum of Squares | 67603.7T |
Arcturus Net Income From Continuing Ops History
About Arcturus Therapeutics Financial Statements
Arcturus Therapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 99.3 M | 104.3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.